Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cocrystal Pharma Inc (NQ: COCP )

1.720 -0.054 (-3.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,063
Open 1.800
Bid (Size) 1.710 (3)
Ask (Size) 1.770 (4)
Prev. Close 1.774
Today's Range 1.706 - 1.800
52wk Range 1.380 - 3.285
Shares Outstanding 10,173,790
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga

Performance

YTD
-17.70%
-17.70%
1 Month
-9.47%
-9.47%
3 Month
-17.70%
-17.70%
6 Month
-32.02%
-32.02%
1 Year
-35.34%
-35.34%

More News

Read More
Recap: Cocrystal Pharma Q3 Earnings
Via Benzinga
Analyst Ratings for Cocrystal Pharma
Via Benzinga
Why Cocrystal Pharma Shares Are Trading Higher Today
Via Benzinga
$2M Bet On Cocrystal Pharma? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate
Via Benzinga
Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast
Via Newsfile
Exposures COVID-19
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A
Via Benzinga
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Cocrystal Pharma to Participate in Two Investor Conferences in November
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Cocrystal Pharma to Present at the LD Micro Main Event XV
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.